Epigenetic targets of Janus kinase inhibitors are linked to genetic risks of rheumatoid arthritis
Abstract Background Current strategies that target cytokines (e.g., tumor necrosis factor (TNF)-α), or signaling molecules (e.g., Janus kinase (JAK)) have advanced the management for allergies and autoimmune diseases. Nevertheless, the molecular mechanism that underpins its clinical efficacy have la...
Saved in:
Main Authors: | Haruka Tsuchiya (Author), Mineto Ota (Author), Haruka Takahashi (Author), Hiroaki Hatano (Author), Megumi Ogawa (Author), Sotaro Nakajima (Author), Risa Yoshihara (Author), Tomohisa Okamura (Author), Shuji Sumitomo (Author), Keishi Fujio (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2024-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Multiomics landscape of synovial fibroblasts in rheumatoid arthritis
by: Haruka Tsuchiya, et al.
Published: (2021) -
Transcriptome analysis of peripheral blood from patients with rheumatoid arthritis: a systematic review
by: Shuji Sumitomo, et al.
Published: (2018) -
Multi-omics approach to precision medicine for immune-mediated diseases
by: Mineto Ota, et al.
Published: (2021) -
Itch and Janus Kinase Inhibitors
by: Yujin Han, et al.
Published: (2023) -
Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne
by: Fabienne Ballanger, et al.
Published: (2023)